Posted 30 May, 2023
Talaris Therapeutics, Inc. appointed Mary Kay Fenton as new CEO
Nasdaq:TALS appointed new Chief Executive Officer Mary Kay Fenton in a 8-K filed on 30 May, 2023.
Effective May 26, 2023, the Board of Directors of the Company (the "Board") appointed Mary Kay Fenton, the Company's Chief Financial Officer, as Interim Chief Executive Officer and President, until a successor is appointed.
Don't how to trade CEO change? Read Reasons for CEO Turnover and Effect on Stock Performance.
Overview of Talaris Therapeutics, Inc.
Health Care/Life Sciences • Biotechnology
Talaris Therapeutics, Inc. is a late-clinical stage cell therapy company, which engages in the development of allogeneic hematopoietic stem cell transplantation. The company was founded by Suzanne Ildstad on February 15, 2002 and is headquartered in Wellesley, MA.Market Cap
$1.02B
View Company Details
$1.02B
Relevant filing section
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Departure of Chief Executive Officer, President and Director As previously announced, effective May 26, 2023, Scott Requadt left his role as Chief Executive Officer and President of Talaris Therapeutics, Inc. (the "Company"). Also on May 26, 2023, the Company and Mr. Requadt entered into a Strategic Advisor Agreement, pursuant to which Mr. Requadt will provide consulting and strategic business activities to the Company as requested through August 26, 2023 in exchange for a monthly retainer of $50,000. The foregoing description of the Strategic Advisor Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Strategic Advisor Agreement, a copy of which will be included as an exhibit to the Company's Quarterly Report on Form 10-Q for the quarter ending June 30, 2023. In addition, on May 26, 2023, Mr. Requadt notified the Company of his intent to resign from the Board, effective immediately. Mr. Requadt's departure was not the result of any disagreement with the Company on any matter relating to the Company's operations, policies or procedures. Appointment of Interim Chief Executive Officer, President and Principal Executive Officer Effective May 26, 2023, the Board of Directors of the Company (the "Board") appointed Mary Kay Fenton, the Company's Chief Financial Officer, as Interim Chief Executive Officer and President, until a successor is appointed. Ms. Fenton will also continue in her role as the Company's Chief Financial Officer and principal financial officer. Ms. Fenton has served as the Company's Chief Financial Officer since March 2021. Ms. Fenton previously served as the Vice President of Strategic Operations, Vertex Cell & Genetic Therapies of Vertex Pharmaceuticals, Inc. (Nasdaq: VRTX) ("Vertex") from October 2019 through February 2021. Ms. Fenton joined Vertex upon completion of the acquisition of Semma Therapeutics, Inc. ("Semma") by Vertex in October 2019. From May 2019 until October 2019, Ms. Fenton served as the Chief Financial Officer and Chief Operating Officer of Semma. From January 2006 until December 2018, Ms. Fenton served as Chief Financial Officer of Achillion Pharmaceuticals, Inc. ("Achillion") (acquired by Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN)), and from October 2000 until January 2006, Ms. Fenton held various financial positions of increasing responsibility at Achillion. Prior to joining Achillion, Ms. Fenton held various positions within the Technology Industry Group at PricewaterhouseCoopers LLP from August 1991 until October 2000. Ms. Fenton also serves on the board of directors of Oncorus, Inc. (Nasdaq: ONCR). Ms. Fenton holds an MBA in finance from the Graduate School of Business at the University of Connecticut and an AB in economics from the College of the Holy Cross. She is a Certified Public Accountant (CPA) (inactive). Ms. Fenton has no family relationship with any of the executive officers or directors of the Company. There are no arrangements or understandings between Ms. Fenton and any other person pursuant to which she was appointed as a principal executive officer of the Company, nor are there any transactions to which the Company is or was a participant in which Ms. Fenton has a material interest subject to disclosure pursuant to Item 404(a) of Regulation S-K, other than as disclosed in the Company's filings with the Securities and Exchange Commission.
Interested in special situations?
Join Tickerverse
- customize event filters
- create watchlists, bookmarks
- get email notifications for the latest special situations
- browse and analyze public companies, executives and SEC filings
Tickerverse is a great way to find investment opportunities in corporate actions.
By signing up you agree to our Terms of Service and Privacy Policy.